RxDoctor Payments Data

Denton Roberts, MD

Ophthalmology · Boise, IDNPI 1699742395

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 38 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Genentech USA, Inc. at 39.8% of the total. Reporting peaked in 2023 at $326 and has fallen 69.3% since, to $100 in 2025. That places this record below the midpoint for ophthalmology clinicians in ID, where the typical reported total is $971.

$842in general payments, 2019–2025

Across 38 payments — averaging $22.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$335
  • Regeneron Healthcare Solutions, Inc.$164
  • Apellis Pharmaceuticals, Inc.$139
  • AbbVie$88
  • Harrow Eye, LLC$28
  • Alcon$26
  • plus $63 from 3 others

What the payments were for

  • Food & beverage$842100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$842 in reported general payments places this provider in the 45th percentile of 60 ophthalmology providers in Idaho.

See all ophthalmology providers in Idaho

Medicare billing

Part B allowed, 2024
$2,821,407
Medicare patients
864
Services billed
34,805

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CombiganBrimonidine Tartrate/Timolol26$5,244
RocklatanNetarsudil Mesylat/Latanoprost11$5,013
Prednisolone Acetate126$3,949
Difluprednate23$1,897
Ketorolac Tromethamine46$1,365
Ofloxacin77$963
Latanoprost117$764
Dorzolamide Hcl42$672
Brimonidine Tartrate20$372
Ondansetron OdtOndansetron50$362
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat21$223
Timolol Maleate47$192
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha16$143
Tramadol Hcl47$92

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCombigan$88$5,24426 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 60 ophthalmology providers in Idaho.

Other ophthalmology in Boise

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →